Search Within

Gynecologic Medicine Service

Formats
  1. Journal Article (1104)
  2. Meeting Abstract (902)
  3. Review (55)
  4. Book Section (46)
  5. Editorial (36)
  6. Guidelines (22)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Solid Tumor Oncology Division (2180)
  2. Department of Medicine (2174)
  3. Gynecology Disease Management Team (1877)
  4. GDMT, Medicine (1859)
  5. Surgery (603)
  6. GDMT, Surgery (479)

More Groups

People
  1. Carol Aghajanian (615)
  2. Nadeem Abu-Rustum (292)
  3. Martee Hensley (290)
  4. Roisin O'Cearbhaill (273)
  5. Vicky Makker (269)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (75)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (458)
  2. Gynecologic Oncology (420)
  3. International Journal of Gynecological Cancer (161)
  4. Annals of Oncology (117)
  5. Clinical Cancer Research (71)
  6. Cancer Research (55)

More Publications

Publishers
  1. American Society of Clinical Oncology (498)
  2. Elsevier B.V. (446)
  3. Lippincott Williams & Wilkins (188)
  4. American Association for Cancer Research (173)
  5. Oxford University Press (144)
  6. Elsevier Inc. (128)

More Publishers

Results (2180)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
    Meeting Abstract

    Lee, C. H.; Shah, A. Y.; Makker, V.; Taylor, M.; Shaffer, D.; Hseih, J. J.; Cohn, A. L.; Di Simone, C.; Marin, A. P.; Rasco, D.; more...
    Asia-Pacific Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)
    Meeting Abstract

    González Martín, A.; Pothuri, B.; Vergote, I. B.; Christensen, R. D.; Graybill, W.; Mirza, M. R.; McCormick, C.; Lorusso, D.; Hoskins, P.; Freyer, G.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)
    Meeting Abstract

    Coleman, R. L.; Fleming, G. F.; Brady, M. F.; Swisher, E.; Steffensen, K. D.; Friedlander, M.; Okamoto, A.; Moore, K.; Ben-Baruch, N.; Werner, T. L.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)
    Meeting Abstract

    Tolaney, S. M.; Wardley, A. M.; Zambelli, S.; Hilton, J.; Troso-Sandoval, T.; Ricci, F.; Im, S. A.; Kim, S. B.; Johnston, S. R. D.; Chan, A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Integrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings
    Meeting Abstract

    Kristeleit, R. S.; Oza, A. M.; Oaknin, A.; Aghajanian, C.; Tinker, A. V.; Tredan, O.; O'Malley, D. M.; Leary, A.; Konecny, G. E.; Lorusso, D.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
    Meeting Abstract

    Lee, C. H.; Shah, A. Y.; Makker, V.; Taylor, M. H.; Shaffer, D.; Hsieh, J. J.; Cohn, A. L.; DiSimone, C.; Pinto Marin, A.; Rasco, D. W.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)
    Meeting Abstract

    Makker, V.; Taylor, M. H.; Aghajanian, C.; Oaknin, A.; Mier, J.; Cohn, A. L.; Romeo Marin, M.; Bratos Lorenzo, R.; Brose, M. S.; DiSimone, C.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial
    Meeting Abstract

    Oaknin, A.; Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours
    Meeting Abstract

    Schram, A. M.; Drilon, A.; Macarulla Mercade, T.; O'Reilly, E. M.; Rodon, J. A.; Wolpin, B. M.; Ou, S. H. I.; Kim, D. W.; Yang, J. C. H.; Lam, Y. C. J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Prospective study evaluating white adipose tissue inflammation and clinicopathologic features in endometrial cancer
    Meeting Abstract

    Moukarzel, L. A.; Stylianou, A.; Wu, M.; Nobre, S. P.; Abu-Rustum, N. R.; Broach, V.; Giri, D. D.; Iyengar, N. M.; Weigelt, B.; Makker, V.
    Annals of Oncology (2019)

    Fulltext@MSK | Save